Related Experiment Video
Updated: May 17, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis
Marie-Anne Morren1, Anne Hoppé, Marleen Renard
1Department of Dermatology, Catholic University of Leuven and University Hospitals Leuven, Leuven, Belgium. Marie-Anne.Morren@uzleuven.be
Abstract:
Diffuse cutaneous mastocytosis is a less common but potentially life-threatening variant of childhood mastocytosis. Here we report 2 children with diffuse cutaneous mastocytosis in whom an activating somatic KIT mutation was detected. Treatment with imatinib, a KIT inhibitor, resulted in resolution of the lesions and were well tolerated by the patients.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Drugs that Stabilize Microtubules
